IL21 and type 1 diabetes mellitus: Participants with T1D and residual β-cell activity, aged 18 to 45, were randomly assigned to one of four groups: liraglutide (1.8 mg daily) plus anti-IL-21, anti-IL-21 alone, or a placebo paired with standard insulin therapy.